SCHEMBL84134

SCHEMBL84134

O=C(O)CN(C(=O)OCc1ccccc1)c1ccccc1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 6/20 0.49
MAPT P10636 1/20 0.49
HPGD P15428 1/20 0.49
TDP1 Q9NUW8 2/20 0.47
MAPK1 P28482 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
SLC6A2 P23975 1/20 0.47
SLC6A3 Q01959 1/20 0.47
KMT2A Q03164 1/20 0.47
CHRM2 P08172 1/20 0.45
CHRM5 P08912 1/20 0.45
CHRM1 P11229 1/20 0.45
CHRM3 P20309 1/20 0.45
LMNA P02545 1/20 0.44
HCAR2 Q8TDS4 1/20 0.44
PAX8 Q06710 2/20 0.43
CCR6 P51684 1/20 0.43
NPC1 O15118 1/20 0.42
GLA P06280 1/20 0.42
HTT P42858 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL11790891 0.98 ALDH1A1 (0.48) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL10915717 0.92 LMNA (0.47) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL1270807 0.92 LMNA (0.51) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL8165909 0.90 FABP7 (0.45) ALDH1A1MAPTHPGDCHRM2CHRM5
SCHEMBL5967396 0.90 KEAP1 (0.47) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL8905179 0.90 ALDH1A1 (0.47) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL7350797 0.87 ALDH1A1 (0.49) ALDH1A1MAPTHPGDTDP1MAPK1
SCHEMBL9686344 0.87 CHRM1 (0.52) KMT2ACHRM2CHRM5CHRM1CHRM3
SCHEMBL5967202 0.87 KEAP1 (0.51) ALDH1A1MAPTHPGDCHRM5CHRM1
Potassium Ion SCHEMBL11790895 0.86 ALDH1A1 (0.49) ALDH1A1MAPTHPGDTDP1MAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 273 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-118085016-B Preparation method of D-phenylglycinyl-glycine 天津卡普希科技有限公司 2024-07-30 CN claimed
CN-118085016-A Preparation method of D-phenylglycinyl-glycine 天津卡普希科技有限公司 2024-05-28 CN claimed
CN-105367510-A Method for preparing (2R,4S)-3-Cbz-2,4-diphenyl-1,3-oxazolidine-5-ketone YE HAIWEI 2016-03-02 CN claimed
CN-105152959-A Synthesis method of (2S, 3S)-3-amino-N-cyclopropyl-2-hydroxyhexanamide hydrochloride SHANGHAI SYNTHEALL PHARMACEUTICAL CO LTD 2015-12-16 CN claimed
EP-0950046-B1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS NAEJA PHARMACEUTICAL INC (CA) 2002-04-10 EP claimed
EP-0950046-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (CA) 1999-10-20 EP claimed
WO-1998012176-A1 3,4-DISUBSTITUTED AZETIDIN-2-ONE DERIVATIVES USEFUL AS CYSTEINE PROTEINASE REGULATORS SYNPHAR LABORATORIES INC. (US) 1998-03-26 WO claimed
US-20260137677-A1 PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 TOCRIS COOKSON LTD (GB) 2026-05-21 US disclosed
EP-4598914-A1 PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 Tocris Cookson Limited (GB) 2025-08-13 EP disclosed
US-20240399776-A1 COLOR DEVELOPER, THERMAL RECORDING MATERIAL, AND THERMAL RECORDING LAYER COATING MATERIAL SANKO CO., LTD. (JP) 2024-12-05 US disclosed
CN-118085016-B Preparation method of D-phenylglycinyl-glycine 天津卡普希科技有限公司 2024-07-30 CN disclosed
CN-118085016-B Preparation method of D-phenylglycinyl-glycine 天津卡普希科技有限公司 2024-07-30 CN disclosed
CN-118085016-A Preparation method of D-phenylglycinyl-glycine 天津卡普希科技有限公司 2024-05-28 CN disclosed
US-4068080-A BETA-LACTAM ANTIBIOTICS, CEPHALOSPORIN ANALOGS BRISTOL-MYERS COMPANY (US) 1978-01-10 US disclosed
US-4068075-A ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1978-01-10 US disclosed
US-4066831-A ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1978-01-03 US disclosed
US-4066832-A ANTIBIOTICS BRISTOL-MYERS COMPANY (US) 1978-01-03 US disclosed
US-4065623-A O-2-Isocephem-4-carboxylic acid derivatives as antibacterial agents BRISTOL-MYERS COMPANY (US) 1977-12-27 US disclosed
US-4012383-A BACTERICIDES BRISTOL-MYERS COMPANY (US) 1977-03-15 US disclosed
US-4011216-A Δ2,3-0-2-Isocephem-4-carboxylic acid and derivatives thereof as antibacterial agents BRISTOL-MYERS COMPANY (US) 1977-03-08 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20260137677-A1 PROTACS USEFUL AGAINST THE MAIN PROTEASE SARS-COV-2 XIAP, MDM2, SARS1 ALDH1A1 4410/4885MAPT 898/4885HPGD 4644/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.